Gsk (GSK) Cash from Investing Activities (2009 - 2026)

Gsk (GSK) has 18 years of Cash from Investing Activities data on file, last reported at -$3.0 billion in Q3 2026.

• For the quarter ending Q3 2026, Cash from Investing Activities changed N/A year-over-year to -$3.0 billion; the trailing twelve-month figure through Sep 2026 stood at $3.0 billion (changed N/A YoY), and the FY2025 full-year result was -$5.6 billion, down 258.41% from the prior year.
• Cash from Investing Activities was -$3.0 billion for Q3 2026 at Gsk, down from $2.7 billion in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $5.4 billion in Q4 2025 to a low of -$4.9 billion in Q4 2022.
• A 5-year average of $410.7 million and a median of $435.5 million in 2023 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities sank 7184.1% in 2022 and jumped 262.83% in 2025, its largest moves.
• Gsk's Cash from Investing Activities stood at -$4.9 billion in 2022, then soared by 187.17% to $4.2 billion in 2023, then fell by 13.15% to $3.7 billion in 2024, then surged by 45.84% to $5.4 billion in 2025, then slumped by 156.49% to -$3.0 billion in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$3.0 billion in Q3 2026, $2.7 billion in Q2 2026, and -$2.0 billion in Q1 2026.